SYNLOGIC, INC. Fair Value Adjustment of Warrants
SYNLOGIC, INC. (SYBX) reported Fair Value Adjustment of Warrants of -$349.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-11
- SYNLOGIC, INC. fair value adjustment of warrants for the quarter ending 2026-06-30 was -$349.00K.
- SYNLOGIC, INC. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$1.87M.
- SYNLOGIC, INC. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$2.70M.
- SYNLOGIC, INC. fair value adjustment of warrants for the quarter ending 2025-09-30 was $1.49M.
- SYNLOGIC, INC. fair value adjustment of warrants for fiscal 2025 was -$2.31M.
- SYNLOGIC, INC. fair value adjustment of warrants for fiscal 2024 was -$16.17M, a 311.36% decline from fiscal 2023.
- SYNLOGIC, INC. fair value adjustment of warrants for fiscal 2023 was $7.65M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 3 month as first filed | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 6 month as first filed | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$349.00K 10-Q · filed 2026-08-11 | -$2.22M 10-Q · filed 2026-08-11 | -$4.92M derived: sum of 3 quarters · filed 2026-08-11 | -$3.44M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2026-03-31 | -$1.87M 10-Q · filed 2026-05-14 | -$4.57M derived: sum of 2 quarters · filed 2026-05-14 | -$3.09M derived: sum of 3 quarters · filed 2026-05-14 | -$3.15M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-12-31 | -$2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$1.21M derived: sum of 2 quarters · filed 2026-03-12 | -$1.28M derived: sum of 3 quarters · filed 2026-08-11 | -$2.31M 10-K · filed 2026-03-12 | ||
| 2025-09-30 | $1.49M 10-Q · filed 2025-11-13 | $1.42M derived: sum of 2 quarters · filed 2026-08-11 | $391.00K 10-Q · filed 2025-11-13 | -$448.00K derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-06-30 | -$67.00K 10-Q · filed 2026-08-11 | -$1.09M 10-Q · filed 2026-08-11 | -$1.93M derived: sum of 3 quarters · filed 2026-08-11 | -$2.31M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | -$1.03M 10-Q · filed 2026-05-14 | -$1.87M derived: sum of 2 quarters · filed 2026-05-14 | -$2.24M derived: sum of 3 quarters · filed 2026-05-14 | -$4.51M derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | -$839.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$1.22M derived: sum of 2 quarters · filed 2026-03-12 | -$3.48M derived: sum of 3 quarters · filed 2026-03-12 | -$16.17M 10-K · filed 2026-03-12 | ||
| 2024-09-30 | -$376.00K 10-Q · filed 2025-11-13 | -$2.65M derived: sum of 2 quarters · filed 2025-11-13 | -$15.33M 10-Q · filed 2025-11-13 | -$7.68M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | -$2.27M 10-Q · filed 2025-08-07 | -$1.20M 10-Q · filed 2024-08-08 | -$14.96M 10-Q · filed 2025-08-07 | -$7.93M 10-Q · filed 2024-08-08 | -$7.31M derived: sum of 3 quarters · filed 2025-08-07 | -$7.31M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$12.69M 10-Q · filed 2025-05-08 | $6.73M 10-Q · filed 2024-05-14 | -$5.04M derived: sum of 2 quarters · filed 2025-05-08 | -$5.04M derived: sum of 3 quarters · filed 2025-05-08 | -$5.04M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $7.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $7.65M derived: sum of 2 quarters · filed 2025-03-06 | $7.65M derived: sum of 3 quarters · filed 2025-03-06 | $7.65M 10-K · filed 2025-03-06 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |